Gabather has completed toxicological studies
Gabather AB has successfully completed the regulatory GLP toxicology studies with GT-002 in rodent and non-rodent animal models. The compound was generally safe and well tolerated in repeated dose administrations for 28 days in animals at dose levels that are expected to exceed a therapeutically relevant dose. Furthermore, safety pharmacology was without any remarks, and GT-002 showed no negative cardiovascular treatment-related effects, which are important safety features for further clinical development of GT-002. "These results support moving forward into the clinic in the near future